Lisata Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Employees: 25

Market Cap: -

Website: http://www.lisata.com

Introduction: Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Clinical Trials

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Phase 3

Completed

Conditions: Refractory Angina Pectoris
Advanced Coronary Heart Disease
Chronic Myocardial Ischemia

Interventions: Biological: Auto-CD34+ cells
Other: Standard of care

First Posted Date: 2012-01-12

Last Posted Date: 2018-12-19

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 291

Registration Number: NCT01508910

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

Phase 2

Completed

Conditions: ST Segment Elevation Myocardial Infarction

Interventions: Other: placebo
Biological: NBS10

First Posted Date: 2011-12-20

Last Posted Date: 2016-04-28

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 195

Registration Number: NCT01495364

Locations: 🇺🇸
St. Joseph's Research Institute, Atlanta, Georgia, United States
🇺🇸
University of Maryland Med Center, Baltimore, Baltimore, Maryland, United States
🇺🇸
Westchester Medical Center, Valhalla, New York, United States

and more 54 locations

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Phase 2

Withdrawn

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: lymphokine-activated killer cells
Drug: polifeprosan 20 with carmustine implant

First Posted Date: 2008-12-25

Last Posted Date: 2019-05-10

Lead Sponsor: Lisata Therapeutics, Inc.

Registration Number: NCT00814593

Locations: 🇺🇸
Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

Completed

Conditions: Myocardial Ischemia

First Posted Date: 2007-10-17

Last Posted Date: 2018-11-28

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 150

Registration Number: NCT00545610

Locations: 🇺🇸
Caritas St. Elizabeth´s Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States

and more 20 locations

ACT34-CMI -- Adult Autologous CD34+ Cells

Phase 2

Completed

Conditions: Myocardial Ischemia

Interventions: Biological: CLBS14 (low-dose)
Biological: CLBS14 (high-dose)
Biological: placebo injection

First Posted Date: 2006-03-08

Last Posted Date: 2021-01-26

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 321

Registration Number: NCT00300053

Locations: 🇺🇸
Northwestern University Medical Center, Bluhm Cardiovascluar Institute, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Scripps Memorial Hospital, La Jolla, California, United States

and more 22 locations